Format

Send to

Choose Destination
Expert Rev Vaccines. 2015 Apr;14(4):589-604. doi: 10.1586/14760584.2014.990386. Epub 2014 Dec 6.

The cost-effectiveness of HPV vaccination in addition to screening: a Dutch perspective.

Author information

1
Department of Pharmacy, Unit of PharmacoEpidemiology and Pharmacoeconomics (PE2), University of Groningen, Groningen, The Netherlands.

Abstract

Addition of the HPV vaccine to available cytological screening has been proposed to increase HPV-related cancer prevention. A comprehensive review on this combined strategy implemented in the Netherlands is lacking. For this review, we therefore analyzed all relevant studies on cost-effectiveness of HPV vaccines in combination with cervical screening in the Netherlands. Most of the studies agree that vaccination in pre-sexual-activity periods of life is cost-effective. Based on published sensitivity analyses, the incremental cost-effectiveness ratio was found to be mainly driven by vaccine cost and discount rates. Fewer vaccine doses, inclusion of additional benefits of these vaccines to prevent HPV-related non-cervical cancers and vaccination of males to further reduce the burden of HPV-induced cancers are three relevant options suggested to be investigated in upcoming economic evaluations.

KEYWORDS:

HPV vaccination; The Netherlands; cervical cancer; cervical cancer screening; costeffectiveness

PMID:
25482311
DOI:
10.1586/14760584.2014.990386
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center